Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, 3 days ago

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.

Uric acid tied to cardiometabolic risk factors in overweight, obese youths

14 Sep 2018

Uric acid is positively associated with blood pressure, insulin and triglycerides in overweight and obese youths, reports a study. A relevant clustering of metabolic risk factors occur as uric acid levels increase, while the risk factor that is less frequently present is elevated blood pressure (BP).

Among participants, boys had significantly higher uric acid than girls. Uric acid showed a positive, significant association with office, daytime and night-time systolic (S)BP, insulin, and triglycerides.

There was a progressive increment in body mass index (BMI), waist circumference, BMI z score, fasting insulin and HOMA index after stratification by sex-specific uric acid tertiles. Such increment was also observed in office and ambulatory SBP among boys.

Similarly, there was an increase in the number of abnormal metabolic risk factors with the uric acid values. The higher the number of metabolic components, the higher the uric acid values.

Furthermore, multiple regression analysis revealed that uric acid significantly correlated with male sex, waist circumference, both office and night-time SBP, and birth weight.

“Further studies need to assess the mechanistic link between uric acid and the cardiometabolic risk factors,” the authors said.

To examine the link between uric acid and individual cardiometabolic risk factors, as well as their degree of clustering, 333 Caucasians of both sexes (149 women; aged 5–18 years) who underwent an assessment of overweight/obesity were recruited. The authors measured anthropometric parameters, office and 24-hour BP measurement and metabolic profiles, including HDL-cholesterol, triglycerides, insulin, HOMA index and uric acid.

“Observational studies have indicated that high levels of serum uric acid are associated with the risk of cardiovascular disease,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, 3 days ago

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.